NASDAQ:CNCE

Concert Pharmaceuticals Competitors

$4.41

-0.21 (-4.55 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.32

Now: $4.41▼

$4.67

50-Day Range

$4.54

MA: $5.66▼

$6.89

52-Week Range

$4.44

Now: $4.41▼

$13.50

Volume312,647 shs

Average Volume484,403 shs

Market Capitalization$141.89 million

P/E RatioN/A

Dividend YieldN/A

Beta0.77

Concert Pharmaceuticals (NASDAQ:CNCE) Vs. MIRM, SIGA, CRNX, ISEE, MGTA, and ALDX

Should you be buying CNCE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Concert Pharmaceuticals, including Mirum Pharmaceuticals (MIRM), SIGA Technologies (SIGA), Crinetics Pharmaceuticals (CRNX), IVERIC bio (ISEE), Magenta Therapeutics (MGTA), and Aldeyra Therapeutics (ALDX).

Concert Pharmaceuticals vs. Mirum Pharmaceuticals Stock

Concert Pharmaceuticals (NASDAQ:CNCE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Risk and Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Mirum Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concert Pharmaceuticals	$1.08 million	131.38	$-78,170,000.00	($3.29)	-1.34
Mirum Pharmaceuticals	N/A	N/A	$-52,550,000.00	($4.58)	-4.03

Mirum Pharmaceuticals has lower revenue, but higher earnings than Concert Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Concert Pharmaceuticals and Mirum Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concert Pharmaceuticals	-921.38%	-55.20%	-44.83%
Mirum Pharmaceuticals	N/A	-61.90%	-54.46%

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 72.9% of Mirum Pharmaceuticals shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 45.5% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Concert Pharmaceuticals and Mirum Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concert Pharmaceuticals	0	0	4	0	3.00
Mirum Pharmaceuticals	0	0	6	1	3.14

Concert Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. Mirum Pharmaceuticals has a consensus target price of $40.1667, suggesting a potential upside of 117.82%. Given Concert Pharmaceuticals' higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Summary

Mirum Pharmaceuticals beats Concert Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Concert Pharmaceuticals vs. SIGA Technologies Stock

Concert Pharmaceuticals (NASDAQ:CNCE) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Risk and Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Concert Pharmaceuticals and SIGA Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concert Pharmaceuticals	$1.08 million	131.38	$-78,170,000.00	($3.29)	-1.34
SIGA Technologies	$26.74 million	20.84	$-7,240,000.00	N/A	N/A

SIGA Technologies has higher revenue and earnings than Concert Pharmaceuticals.

Profitability

This table compares Concert Pharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concert Pharmaceuticals	-921.38%	-55.20%	-44.83%
SIGA Technologies	34.62%	37.31%	25.33%

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 29.3% of SIGA Technologies shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Concert Pharmaceuticals and SIGA Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concert Pharmaceuticals	0	0	4	0	3.00
SIGA Technologies	0	0	0	0	N/A

Concert Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. Given Concert Pharmaceuticals' higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than SIGA Technologies.

Concert Pharmaceuticals vs. Crinetics Pharmaceuticals Stock

Concert Pharmaceuticals (NASDAQ:CNCE) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Crinetics Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concert Pharmaceuticals	$1.08 million	131.38	$-78,170,000.00	($3.29)	-1.34
Crinetics Pharmaceuticals	$1.19 million	464.35	$-50,420,000.00	($2.09)	-8.00

Crinetics Pharmaceuticals has higher revenue and earnings than Concert Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Institutional & Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Concert Pharmaceuticals and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concert Pharmaceuticals	-921.38%	-55.20%	-44.83%
Crinetics Pharmaceuticals	N/A	-43.35%	-39.73%

Analyst Ratings

This is a summary of current recommendations for Concert Pharmaceuticals and Crinetics Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concert Pharmaceuticals	0	0	4	0	3.00
Crinetics Pharmaceuticals	0	1	3	0	2.75

Concert Pharmaceuticals currently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. Crinetics Pharmaceuticals has a consensus target price of $35.00, suggesting a potential upside of 109.21%. Given Concert Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats Concert Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Concert Pharmaceuticals vs. IVERIC bio Stock

Concert Pharmaceuticals (NASDAQ:CNCE) and IVERIC bio (NASDAQ:ISEE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Risk & Volatility

Concert Pharmaceuticals has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, IVERIC bio has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Institutional and Insider Ownership

69.7% of Concert Pharmaceuticals shares are held by institutional investors. Comparatively, 84.8% of IVERIC bio shares are held by institutional investors. 10.1% of Concert Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of IVERIC bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Concert Pharmaceuticals and IVERIC bio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concert Pharmaceuticals	-921.38%	-55.20%	-44.83%
IVERIC bio	N/A	-45.42%	-41.94%

Valuation & Earnings

This table compares Concert Pharmaceuticals and IVERIC bio's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concert Pharmaceuticals	$1.08 million	131.38	$-78,170,000.00	($3.29)	-1.34
IVERIC bio	N/A	N/A	$-58,860,000.00	($1.39)	-4.28

IVERIC bio has lower revenue, but higher earnings than Concert Pharmaceuticals. IVERIC bio is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Concert Pharmaceuticals and IVERIC bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concert Pharmaceuticals	0	0	4	0	3.00
IVERIC bio	0	1	1	0	2.50

Concert Pharmaceuticals presently has a consensus target price of $20.50, suggesting a potential upside of 364.85%. IVERIC bio has a consensus target price of $13.00, suggesting a potential upside of 118.49%. Given Concert Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Concert Pharmaceuticals is more favorable than IVERIC bio.

Summary

IVERIC bio beats Concert Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Concert Pharmaceuticals vs. Magenta Therapeutics Stock

Magenta Therapeutics (NASDAQ:MGTA) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings & Valuation

This table compares Magenta Therapeutics and Concert Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Magenta Therapeutics	N/A	N/A	$-76,770,000.00	($2.07)	-5.31
Concert Pharmaceuticals	$1.08 million	131.38	$-78,170,000.00	($3.29)	-1.34

Magenta Therapeutics has higher earnings, but lower revenue than Concert Pharmaceuticals. Magenta Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Magenta Therapeutics and Concert Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Magenta Therapeutics	N/A	-53.42%	-47.67%
Concert Pharmaceuticals	-921.38%	-55.20%	-44.83%

Volatility & Risk

Magenta Therapeutics has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Institutional and Insider Ownership

59.3% of Magenta Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Concert Pharmaceuticals shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by insiders. Comparatively, 10.1% of Concert Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Magenta Therapeutics and Concert Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Magenta Therapeutics	0	0	4	0	3.00
Concert Pharmaceuticals	0	0	4	0	3.00

Magenta Therapeutics currently has a consensus price target of $17.6667, suggesting a potential upside of 60.61%. Concert Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 364.85%. Given Concert Pharmaceuticals' higher probable upside, analysts plainly believe Concert Pharmaceuticals is more favorable than Magenta Therapeutics.

Summary

Magenta Therapeutics beats Concert Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Concert Pharmaceuticals vs. Aldeyra Therapeutics Stock

Concert Pharmaceuticals (NASDAQ:CNCE) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Concert Pharmaceuticals and Aldeyra Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concert Pharmaceuticals	$1.08 million	131.38	$-78,170,000.00	($3.29)	-1.34
Aldeyra Therapeutics	N/A	N/A	$-60,830,000.00	($2.05)	-5.50

Aldeyra Therapeutics has lower revenue, but higher earnings than Concert Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Concert Pharmaceuticals and Aldeyra Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concert Pharmaceuticals	-921.38%	-55.20%	-44.83%
Aldeyra Therapeutics	N/A	-73.73%	-52.74%

Risk & Volatility

Concert Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Institutional and Insider Ownership

69.7% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Concert Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concert Pharmaceuticals	0	0	4	0	3.00
Aldeyra Therapeutics	0	1	10	0	2.91

Concert Pharmaceuticals currently has a consensus price target of $20.50, suggesting a potential upside of 364.85%. Aldeyra Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 130.50%. Given Concert Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Concert Pharmaceuticals is more favorable than Aldeyra Therapeutics.

Summary

Concert Pharmaceuticals beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.